Apr 25 |
RVPH: Full Year 2023 Results
|
Apr 15 |
Reviva Pharmaceuticals FY Non-GAAP EPS of -$1.65 beats by $0.01
|
Apr 15 |
Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment
|
Apr 15 |
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
|
Apr 15 |
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
|
Apr 15 |
RVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER Data
|
Mar 28 |
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
|
Mar 26 |
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
|
Mar 11 |
Reviva to Present at the UBS Virtual CNS Day
|
Mar 7 |
Reviva to Present at the 36th Annual ROTH Conference
|